Drug Profile
CLT 28643
Alternative Names: Cl 28643; CL-28643Latest Information Update: 28 Aug 2021
Price :
$50
*
At a glance
- Originator Clanotech
- Class Anti-inflammatories; Antifibrotics; Eye disorder therapies
- Mechanism of Action Integrin alpha 5 beta 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Eye disorders
- Discontinued Cancer
Most Recent Events
- 28 Aug 2021 No recent reports of development identified for preclinical development in Eye-disorders in USA (PO)
- 20 Aug 2019 Preclinical development for eye disorders is ongoing in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA (PO)